Reassembling of albumin-bound paclitaxel mitigates myelosuppression and improves its antitumoral efficacy via neutrophil-mediated targeting drug delivery

Albumin-bound paclitaxel (abPTX) has been widely used in cancer treatment. However, dose-related side effects, such as myelosuppression, restrict its clinical application. Cell-based targeting drug delivery is a promising way to mitigate systematic side-effects and improve antitumoral efficacy. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuxin, Han, Lulu, Qiu, Xiaoyan, Wang, Meng, Chen, Zheng, Cai, Ying, Xin, Yong, Lv, Yanfang, Hu, Ankang, Chai, Dafei, Li, Liantao, Li, Huizhong, Zheng, Junnian, Wang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903760/
https://www.ncbi.nlm.nih.gov/pubmed/35244505
http://dx.doi.org/10.1080/10717544.2022.2046892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903760/
https://www.ncbi.nlm.nih.gov/pubmed/35244505
http://dx.doi.org/10.1080/10717544.2022.2046892

Ejemplares similares